T cell compositions with improved phenotypic properties

By preparing CD8+ T cell compositions containing TSCM, the problem of the short-lasting effect of adoptive immunotherapy in the prior art is solved, and a robust and long-lasting therapeutic effect is achieved, and the destructive ability of target cells is improved.

CN118903396APending Publication Date: 2024-11-08NEXIMMUNE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410616338.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-06-27
Filing Date
2019-11-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing adoptive immunotherapy is difficult to produce sufficient clinically valuable engineered cytotoxic lymphocytes and cannot provide sustained and lasting therapeutic effects, resulting in tumor recurrence and complications.

Method used

Provided is a composition comprising about 106 CD8+ T cells specific for the target peptide antigen, and comprising T memory stem cells (TSCM), prepared by enrichment and amplification processes to ensure at least 1% to 50% of the composition. TSCM provides robust and long-lasting adoptive treatment.

Benefits of technology

A robust and long-lasting adoptive therapy effect was achieved, which improved the destructive ability and immune reconstruction ability of target cells, and reduced the emergence of depleted T cell phenotype and toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903396A_ABST
    Figure CN118903396A_ABST
Patent Text Reader

Abstract

The present invention provides an isolated cell composition, which, in some embodiments, is suitable for use in adoptive immunotherapy; as well as methods of making the cell compositions and methods of treatment using the cell compositions. The present invention relates to compositions comprising at least about 106 CD8 + T cells specific for one or more target peptide antigens in a pharmaceutically acceptable carrier, the compositions comprising T memory stem cells (TSCMs). In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing robust and lasting adoptive therapy, as well as T cell engineering progression.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application with application number 201980087076.3, application date November 8, 2019, and invention name “T cell composition with improved phenotypic characteristics”.

[0002] priority

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 757,467, filed on November 8, 2018, U.S. Provisional Application No. 62 / 821,031, filed on March 20, 2019, and U.S. Provisional Application No. 62 / 867,499, filed on June 27, 2019, each of which is incorporated herein by reference in its entirety. Background Art

[0004] Immunotherapy has become the cornerstone of cancer treatment, and it includes multiple strategies that are intended to release, guide and enhance the patient's own immune system by adoptive transfer of amplified natural circulation or genetically engineered cytotoxic lymphocytes. Although there are recent advances in the field, current adoptive immunotherapy is still faced with several challenges. For example, many adoptive immunotherapy cannot produce enough levels of engineered cytotoxic lymphocytes with clinical or therapeutic value from peripheral blood, or cannot uniformly engineer effector cells, or cannot provide continuous and lasting therapeutic effects for patients, thereby causing tumor recurrence and other complications. Therefore, there is a significant demand for providing a more effective, lasting and safer adoptive immunotherapy selection (including for patients with leukemia or lymphoma (including acute or chronic leukemia) and other patients who can benefit from adoptive immunotherapy) cell composition. In various aspects and embodiments, the present invention solves these needs. Summary of the invention

[0005] In various aspects and embodiments, the present invention provides an isolated cell composition suitable for adoptive immunotherapy and / or genetic engineering of T cells. The present invention further provides methods of making the cell composition and methods of using the cell composition for treatment. The composition comprises at least about 10 6 CD8+ T cells specific for one or more target peptide antigens, and the composition comprises T memory stem cells (T SCM In various embodiments, the CD8+ T cells are at least about 1% of T memory stem cells. In some embodiments, the T memory stem cells are isolated to prepare a preparation that substantially comprises T memory stem cells (e.g., 70% to 100% T SCM ) composition. Due to the presence of significant levels of T SCMThe compositions of the present invention can provide robust and durable adoptive therapy. The cell compositions need not contain T cells expressing chimeric antigen receptors or recombinant TCRs, and thus, in various embodiments, provide an alternative to these technologies that often produce more exhaustive T cell phenotypes and less durable responses and greater toxicity. In other embodiments, the T SCM It is used to recombinantly express chimeric antigen receptors or heterologous TCRs to generate engineered T cells with high proliferation capacity and a less exhausted phenotype.

[0006] In various embodiments, the cell composition comprises at least 1% or at least 15% T memory stem cells and about 10 6 CD8+ T cells specific for the target peptide antigen, or at least about 10 7 At least about 10 8 or at least about 10 9 or at least about 10 10 CD8+ T cells specific for target peptide antigens are prepared to provide robust target cell destruction and long persistence in vivo. For example, to treat acute myeloid leukemia (AML) or myelodysplastic syndrome, the cell composition may include T cells specific for WT1, PRAME, Survivin, and cyclin A1 peptide antigens.

[0007] In various embodiments, the cell composition comprises about 1% to about 50% T memory stem cells, or about 5% to about 25% T memory stem cells. In various embodiments, the T cells are at least 5% T memory stem cells, or the T cells are at least about 10% T memory stem cells, or the T cells are at least 20% T memory stem cells or at least 25% T memory stem cells, which provide an adoptive immunotherapy composition with significant proliferation potential, immune reconstitution capacity and lifespan.

[0008] In various embodiments, greater than 95% of the CD8+ T cells in the composition comprise a memory phenotype. SCM In addition, the memory phenotype also includes central memory T cells (T CM ), effector memory T cells (T EM ) and effector memory RA+ T cells (T EMRA ). In some embodiments, at least 80% of the memory phenotypes are T SCM , T CM and T EM .

[0009] In various embodiments, except for T SCMIn addition, the CD8+ T cells in the composition also include central memory T cells and effector memory T cells. In various embodiments, the T cells (and / or T cells specific for the target antigen) in the composition are at least about 30% central memory T cells or effector memory cells, or in some embodiments at least about 50% central memory T cells or effector memory T cells, or in some embodiments at least about 70% central memory T cells or effector memory T cells, or in some embodiments at least about 80% central memory T cells or effector memory T cells, or in some embodiments at least about 90% central memory T cells or effector memory T cells. In some embodiments, the CD8+ T cells specific for one or more target antigens are at least 50% central memory T cells and effector memory T cells, or in some embodiments at least 80% central memory T cells and effector memory T cells. In some embodiments, T SCM With T CM The combination is about 40% to about 70% of the CD8+ T cells.

[0010] In some embodiments, the cell composition comprises less than about 20% or less than about 10% terminally differentiated memory T cells (e.g., T EMRA In some embodiments, the phenotype of the cells can be created and / or controlled using an enrichment and expansion process using paramagnetic artificial antigen presenting cells (aAPCs) and a mixture of recombinant T cell growth factors.

[0011] In various embodiments, the cell composition is at least about 70%, or at least about 80%, or at least about 90% CD8+ or CD4- T cells (e.g., CD3+CD8+ or CD3+CD4- cells). For example, the isolated cell composition may be characterized as having less than about 10% or less than about 5% CD4+ T cells. When CD8+ T cells are expanded ex vivo, CD4+ cells have a tendency to overgrow CD8+ cells and compete for growth signals, and exogenous CD4+ cells are not necessary for a robust and durable in vivo response.

[0012] In various embodiments, the antigen-specific T cells display a multifunctional phenotype after activation. In some embodiments, at least 10% of CD8+ T cells, or in some embodiments at least 20% of CD8+ T cells, or in some embodiments at least 40% of CD8+ T cells display a multifunctional phenotype after activation. For example, T cells are positive for two or more of the following after activation: intracellular staining for IL-2, IFN-γ production, TNF-α production, and CD107A. In various embodiments, at least 20% of antigen-specific T cells display at least two of these markers. In various embodiments, at least 20% of antigen-specific T cells display at least three of these markers, or in some embodiments, display all four of these markers. In various embodiments, at least 5% of CD8+ T cells are multi-antigenic, which means that CD8+ T cells are able to respond to multiple tumor or viral antigens in vitro or in vivo.

[0013] In various embodiments, the cell composition further comprises γδT cells. γδT cells have a unique T cell receptor (TCR) on their surface. γδT cells can play a role in recognizing lipid antigens and phosphoantigens, and can provide HLA-independent anti-pathogen and anti-tumor mechanisms. In addition, γδT cells can provide help for CD8+ cells. The clinical significance of γδT cells in the context of hematopoietic stem cell transplantation (HSCT) has been observed, and in particular, the higher frequency of γδT cells after transplantation is associated with favorable outcomes.

[0014] Cell compositions according to various embodiments can be prepared by enrichment and amplification processes. In some embodiments, CD8+ cells with specificity for one or more target antigens (such as tumor-associated antigens or virus-associated antigens) are enriched. Even when the source lymphocytes are mainly naive cells, this cell colony can also be rapidly amplified in culture to reach the cell composition described herein. Enrichment can be carried out using paramagnetic beads to actively select cell colonies, and due to the powerful magnetic aggregation of T cell surface receptors, it can have the additional advantage of activating naive cells and other T cell colonies. For example, paramagnetic beads or nanoparticles may contain monomers or polymeric (for example, dimerized) HLA ligands presenting peptide antigens, and costimulatory signals on the same or different particles, such as CD28 agonists (for example, CD28 antibody agonists). In some embodiments, CD28+ cells are also enriched, which can be carried out simultaneously with antigen-specific enrichment.

[0015] In various embodiments, the target peptide antigen is a tumor or cancer-associated antigen, including tumor-derived, tumor-specific antigens and neoantigens. T cells specific for tumor-associated antigens are often very rare and in many cases undetectable in the peripheral blood of healthy individuals. This is often the difference observed between virus-specific T cells and tumor antigen-specific T cells.

[0016] In some embodiments, the target peptide antigen includes at least one antigen associated with or derived from a pathogen, such as a viral, bacterial, fungal, or parasitic pathogen. For example, at least one peptide antigen may be associated with HIV, hepatitis (e.g., type B, C, or D) CMV, Epstein-Barr virus (EBV), influenza, herpes virus (e.g., HSV 1 or 2 or varicella zoster), and adenovirus. For example, CMV is the most common viral pathogen found in organ transplant patients and is the leading cause of morbidity and mortality in patients receiving bone marrow or peripheral blood stem cell transplants. Viral activation is known to be implicated in cancer biology.

[0017] In other embodiments, the cell composition comprises T cells specific for tumor-associated antigens, wherein pathogen-associated antigen-specific T cells are provided as bystander cells. Other bystander cells include γδT cells. In particular, by enriching HLA peptides and anti-CD28, bystander cells will be enriched and expanded, especially when a mixture of T cell growth factors that can drive some non-specific expansion of these cells in the absence of antigen-specific activation is used. In these embodiments, although most of the composition is T cells specific for the target peptide (e.g., from 5% to 75%), the remaining T cells (from about 0.25% to about 25%) provide some immune system reconstruction against common pathogens, which is particularly beneficial after transplantation or in cancers with viral etiology.

[0018] Some embodiments use T cell growth factors that affect the proliferation and / or differentiation of T cells during expansion. Particularly useful cytokines include MIP-1β, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IL-21 and INF-γ. In these or other embodiments, the cells are expanded in culture in the presence of a cytokine mixture comprising one, two or three cytokines selected from MIP-1β, IL-1β and IL-6. In some embodiments, the cytokine further comprises IL-10. In some embodiments, the growth factor comprises IL-2, IL-4, IL-6, INF-γ and IL-1β or is substantially composed of IL-2, IL-4, IL-6, INF-γ and IL-1β. Cells can be expanded in culture for 1 to 4 weeks, such as about 10 days to about 21 days.

[0019] In other aspects, the present invention provides a method for making a cell composition, the method comprising enriching and amplifying with aAPC as described herein. In particular, after depleting CD4+ cells from source lymphocytes (e.g., from healthy donors or from patients in need of adoptive immunotherapy), T cells specific to target peptide antigens and in some embodiments CD28+ cells are enriched for antigen-specific CD8+ T cells. Target cells can be enriched using nanoparticles or microparticles aAPC (such as superparamagnetic nanoparticles that activate T cells in vitro by magnetic field-induced cell surface receptor aggregation). Other materials including latex or other polymer-based nanoparticles can also be used to aggregate cell surface receptors (aggregation without magnetic induction). Then, the enriched T cells can be rapidly amplified in vitro, including the use of reconstructed T cell growth factors (e.g., factors comprising MIP-1β, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, IL-21, IFN-γ). In some embodiments, the cells are expanded in culture in the presence of one, two or three cytokines selected from MIP-1β, IL-1β, IL-6 and IL-10. In some embodiments, the growth factors include IL-2, IL-4, IL-6, INF-γ and IL-1β or are essentially composed of IL-2, IL-4, IL-6, INF-γ and IL-1β. In various embodiments, these cytokines are used in combination with artificial or natural antigen presenting cells to expand antigen-specific T cells.

[0020] In other aspects, the present invention provides methods for adoptive cell therapy, including methods for treating patients with cancer and / or patients who have undergone allogeneic stem cell transplantation, wherein the patient has received or has not received lymphocyte depletion therapy, tumor reduction therapy, immunomodulatory therapy (before administering cell therapy). The cell therapy may further provide or not provide cytokine support after treatment. In some embodiments, the patient suffers from hematological cancer, which in some embodiments relapses after allogeneic stem cell transplantation. In some embodiments, the patient suffers from acute myeloid leukemia (AML) or myelodysplastic syndrome. For example, in some embodiments, the cell composition comprises T cells specific to WT1, PRAME, survivin and cyclin A1 peptide antigens. However, in other embodiments, cancer includes various types of solid tumors, including cancer, sarcoma and lymphoma. Exemplary target peptide antigens are described herein.

[0021] In some embodiments, the patient suffers from an infectious disease or is at risk of an infectious disease. For example, a patient who has undergone HSCT is at a specific risk of an infectious disease due to an immunocompromised state. Infectious diseases that can be treated or prevented include infectious diseases caused by bacteria, viruses, prions, fungi, parasites, worms, etc. Such diseases include AIDS, hepatitis B / C, CMV infection, Epstein-Barr virus (EBV) infection, influenza, herpes virus infection (including herpes zoster) and adenovirus infection.

[0022] In other embodiments, the present invention provides a method for preparing a γδT cell colony. The method includes amplifying a cell colony comprising γδT cells in the presence of two or more of IL-2, IL-4, IL-6, INF-γ, and IL-1β. Prior to amplification, the cell colony comprises less than about 20% or less than about 10% or less than about 8% of γδT cells. In some embodiments, the cell colony is CD28-enriched. In some embodiments, the cell colony is CD4+ depleted. Amplification of cells in culture may be performed as described herein, such as 1-4 weeks. γδT cells may be separated from other cells using known methods such as cell sorting, and may be provided as a cell composition for adoptive transfer or research purposes, and may alternatively be modified to express one or more heterologous or engineered genes, such as heterologous or engineered T cell receptors (e.g., αβTCR), including chimeric antigen receptors (CAR).

[0023] Other aspects and embodiments will be apparent from the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 is an image showing the artificial immune modulation (AIM) platform for generating CD8+ antigen-specific T cells.

[0025] Figure 2 is an image showing AIMACT (Adoptive Cell Therapy) and Enrichment and Expansion (E+E) cell expansion system, which enables rapid in vitro enrichment and expansion of antigen-specific T cells.

[0026] Figure 3 There are two figures showing the enrichment and expansion of antigen-specific cell products for the AIMACT platform. The figure on the left shows the enrichment and expansion of antigen-specific cell products for the AIMACT platform. 37-45 , 126-134 ,PRAME 425 and cyclin A1 227-235 , 341-351Total number of CD8+ T cells generated from fresh PBMCs of four healthy donors after ex vivo enrichment and expansion. The graph on the right shows the total percentage of the same acute myeloid leukemia (AML) specific antigens after ex vivo enrichment and expansion of CD8+ T cells.

[0027] Figure 4A and Figure 4B It was shown that CD8+ T cells generated by the AIMACT platform contained memory T cells. Figure 4A AML antigen-specific CD8+ T cell populations are shown after enrichment but before expansion at day 0 (top) and after expansion at day 14 (bottom). CM = central memory T cells (CD62L+, CD45RA-); T N = naive T cells (CD62L+, CD45RA+); T EM = effector memory T cells (CD62L-, CD45RA-); T EMRA = effector memory RA+ T cells (CD62L-, CD45RA+); T SCM =T memory stem cells (CD62L+, CD45RA+, CD95+). Figure 4B WT1, a specific antigen in AML 37-45 , 126-134 ,PRAME 425 , Cyclin A1 227-235 , 341-351 On day 14 after AML-specific enrichment and expansion, T SCM , T CM , T EM and T EMRA Memory T cell phenotype.

[0028] Figure 5A and Figure 5B The results showed that AML-specific T cells enriched and expanded ex vivo had a highly polyfunctional phenotype, including intracellular staining for IL-2 (proliferation and memory), IFN-γ (activation of other T cells, memory, MHC upregulation), TNF-α (proinflammatory), and CD107A (granzyme release, cytotoxic activity). The vast majority of AML-specific T cells (i.e., approximately 62%) exhibited 3-4 effector functions upon nonspecific stimulation ( Figure 5A , top). Figure 5A In (bottom), the graph shows the percentage of T cells expressing IL-2, TNF-α, IFN-γ and CD107A. Figure 5A In the present study, T cells were stimulated by nonspecific stimulation of peptide-pulsed T2 cells. Figure 5B In this study, we showed the use of WT1 from a human AML-specific antigen 37-45 ,126-134 ,PRAME 425 and cyclin A1 227-235 , 341-351 Figure 3 shows T cell-mediated tumor-specific killing of the AML cell line U266 by CTLs generated from fresh PBMCs of healthy donors at two effector to target (E:T) ratios of 10:1 (left bar) and 20:1 (right bar).

[0029] Figure 6 Composed of four graphs comparing the specificity of Mart-1 specific T cells generated by the enrichment and expansion process between melanoma patient-derived PBMCs (top) and healthy donor-derived PBMCs (bottom). Regardless of the donor source, the enrichment and expansion process produces a consistent cell composition. The data in this experiment were generated from frozen PBMCs.

[0030] Figure 7 The results show that the AIMACT-based E+E process generates a TCR library that mimics the natural immune response, thereby providing robust adoptive therapy from a natural T cell pool that has undergone natural selection. The breadth of the polyclonal TCR library enables a natural and durable immune response.

[0031] Figure 8 The E+E process produces a large number of multiple myeloma antigen-specific T memory stem cells (T SCM )((CD62L+, CD45RA+, CD95+). The figure shows the phenotype of multiple myeloma-specific antigen T cells before and after expansion from healthy donor leucopak.

[0032] Fig. 9A The phenotype of T cells from ex vivo batch enrichment and expansion of multiple myeloma antigen-specific T cells from healthy donor leucopak is shown. The figure shows that the E+E process produced a large number of antigen-specific CD8+ T cells (based on hinge dimer staining, about 1.6x10 9 CD8+ T cells), which include T memory stem cells (T SCM ), central memory T cells T CM and effector memory T cells (T EM ). Fig. 9B The phenotype of T cells enriched and expanded in vitro from multiple myeloma antigen-specific T cells of four different clinical multiple myeloma patients is shown. The figure shows that the enrichment and expansion process produces a large number of antigen-specific CD8+ T cells, including T memory stem cells (T SCM ), central memory T cells T CM and effector memory T cells (T EM ).

[0033] Fig.10 The generation of γδ T cells, including Vδ1 and Vδ2 TCR subtypes, is shown.

[0034] Fig.11 Shown are the percentages of γδ T cells at day 14 after expansion of various antigen-specific T cells (AML, MM, EBV, MART-1). The percentages of γδ T cells at day 14 correlated broadly with the number of γδ T cells at day 0. DETAILED DESCRIPTION

[0035] T cell memory is compositionally heterogeneous, consisting of stable, quiescent, phenotypically distinct subsets of surface markers that are able to generate unique functional responses upon stimulation. CM ), effector memory T cells (T EM ), effector memory RA+ T cells (T EMRA ) and T memory stem cells (T SCM Memory T cells are formed when antigen-specific naive CD4+ or CD8+ T cells are activated after antigen exposure and subsequently undergo proliferative expansion and differentiation. Therefore, persistent memory is essential for long-term protection against infection and malignancy. It has been shown that only T memory cells SCM Subset cells differentiate into central memory T cells (T CM ), effector memory T cells (T EM ) and terminal effector T cells (T TE However, T memory stem cells are rare and account for a small fraction of circulating lymphocytes. It is currently not feasible to generate clinically relevant quantities of T memory stem cells, for example for adoptive immunotherapy. Therefore, there is a need for methods that can generate, expand, and SCM cells and enable antigen redirection techniques to target cancer and infectious diseases.

[0036] Disclosed herein are isolated cell compositions having at least about 10 6 CD8+ T cells specific for one or more target peptide antigens and containing T SCM Cells. T cells of the present disclosure SCM The cells express surface markers similar to those of naive T cells, but express elevated levels of the CD95 surface marker. SCM The cells are the least differentiated and expanded memory subset. Compared with other memory subsets, the T cells of the present disclosure SCM The cells show a huge proliferation capacity, are able to reconstitute the entire pool of memory T cells and effector T cells, and are a long-term stable population of cells with excellent homeostasis and differentiation capacity.6 CD8+ T cells specific for one or more target peptide antigens and containing T SCM The composition of the cells provides a highly effective anti-tumor composition that can be used to produce, expand T cells in clinically relevant quantities for therapeutic applications. SCM cells and enable the cells to be redirected against cancer cells.

[0037] In various aspects and embodiments, the present invention provides isolated cell compositions, methods of making the cell compositions, and methods of using the cell compositions for treatment. In some embodiments, the cell compositions are used for adoptive cell therapy. The compositions comprise at least about 10 6 CD8+ T cells specific for one or more target peptide antigens and containing T SCM In various embodiments, the CD8+ T cells are at least about 1% of the T SCM In some embodiments, the isolated T SCM cells, thereby preparing a cell line containing nearly 100% T memory stem cells (e.g., at least 90% T SCM In some embodiments, a composition of about 70% to about 100% T memory stem cells is produced. Due to the presence of significant levels of T memory stem cells, the composition of the present invention provides a robust and durable adoptive therapy. The cell composition does not have to include T cells expressing a chimeric antigen receptor (CAR) or a recombinant TCR, and therefore in various embodiments, provides an alternative to those technologies that often produce a more exhaustive T cell phenotype and a less persistent response. In other embodiments, T SCM It is used to recombinantly express chimeric antigen receptors or heterologous TCRs (e.g., αβTCRs or γδTCRs) to produce engineered T cells with high proliferative capacity and a phenotype that is less prone to exhaustion than previously described. SCM The cells can be used to engineer T cells using CAR or heterologous TCR.

[0038] As used herein, the term "one or more target peptide antigens" or "target antigen" refers to peptide antigens that are used ex vivo, for example, in conjunction with artificial antigen presenting cells (aAPC) or professional antigen presenting cells (pAPC) platforms (e.g., dendritic cells) to enrich and / or expand the desired CD8+ cell population. aAPC or pAPC are used to activate and expand CTLs from donor or patient lymphocytes. In some embodiments, the target peptide antigen is a peptide epitope loaded onto aAPC for ex vivo enrichment and expansion of specific CD8+ T cells. Therefore, the term "specific for a target peptide antigen" means that the T cell is an antigen that has experienced the target antigen together with the target antigen.

[0039] In various embodiments, the cell composition comprises at least about 10 6 CD8+ T cells specific for the target peptide antigen, or at least about 10 7 CD8+ T cells specific for the target peptide antigen, or at least about 10 8 At least about 10 9 or at least about 10 10 CD8+ T cells specific for the target peptide antigen to provide robust target cell destruction. In some embodiments, the cell composition contains 1x10 7 Up to 1x10 9 CD8+ T cells specific for the target antigen, or in some embodiments, 5x10 7 Up to 5x10 8 CD8+ T cells specific for the target antigen. For example, the composition may contain from about 5x10 5 About 5x10 6 In some embodiments, the volume of the composition is ≤100ml (e.g., 50 to 100ml). In various embodiments, the cells of the composition are at least 70% alive or at least about 80% or about 90% alive, and provided in a sterile medium, the culture medium can be a cryoprotectant medium (e.g., 10% DMSO). The medium can be an aqueous medium suitable for intravenous infusion, for example, including water and electrolytes. An exemplary medium is PLASMALYTE.

[0040] Disclosed herein is a cell composition comprising CD8+ cytotoxic lymphocytes (CTLs) and memory T cells. The CTLs disclosed herein include the following T cell populations: initial cells, T memory stem cells, central memory cells, effector memory cells, and terminally differentiated memory cells. According to an embodiment of the present invention, T cells specific for a target antigen include a large number of T SCM Cells. In various embodiments, the T cells specific for the target antigen also include central memory T cells and effector memory T cells. The cell composition provides a persistent response, including in some embodiments antigen-specific T cells that persist in vivo for at least about 6 months, or at least about 12 months, or at least about 18 months, or at least about two years.

[0041] Naive T cells have differentiated in the bone marrow and have successfully undergone the positive and negative central selection process in the thymus. Naive T cells are considered mature and, unlike activated or memory T cells, have not encountered their cognate antigens. Naive T cells can be characterized by the surface expression of L-selectin (CD62L) and the absence of activation surface markers. In the naive state, T cells are generally static and do not divide. According to the present disclosure, naive T cells are defined as CD62L+ and CD45RA+.

[0042] Memory T cells include T memory stem cells (T SCM ), central memory T cells and effector memory T cells. Memory T cells previously responded to their cognate antigens. When encountering the cognate antigen for the second time, memory T cells can multiply to form a faster and stronger immune response. Memory T cells include at least T memory stem cells, effector memory T cells and central memory T cells. Memory T cell subtypes have a long lifespan and can rapidly expand into a large number of effector T cells after being re-exposed to their cognate antigens.

[0043] T memory stem cells (T scm ) is defined herein as CD45RA+, and is defined as having at least the following surface markers: CD62L+, CD45RA+, and CD95+. In some embodiments, the T memory stem cells disclosed herein are CD62L+, CD45RA+, CD95+, and may have one or more of the following surface markers: CD28+, CD27+, CXCR3+CD11a+, IL-2Rβ+, CD58+, and CD57-. In some embodiments, the T memory stem cells comprise cells that are CD62L+, CD45RA+, CD28+, CD27+, and CD95+. In some embodiments, the T memory stem cells comprise cells that are CD62L+, CD45RA+, CD95+, and CXCR3+. In some embodiments, the T memory stem cells comprise cells that are CD62L+, CD45RA+, CD95+, and CD11a+. In some embodiments, T memory stem cells comprise cells that are CD62L+, CD45RA+, CD95+, and IL-2Rβ+. In some embodiments, T memory stem cells comprise cells that are CD62L+, CD45RA+, CD95+, and CD58+. In some embodiments, T memory stem cells comprise cells that are CD62L+, CD45RA+, CD95+, and CD57-. This memory subset has stem cell-like self-renewal capacity and the ability to reconstruct the multipotency of memory T cells and effector T cell subsets. T SCM T cells typically represent a small fraction (e.g., >5%) of circulating T lymphocytes and have the ability to rapidly proliferate and release inflammatory cytokines in response to antigen re-exposure. SCMThe cells are a subset of the memory T cell subset. SCM Cells can be created and / or controlled as disclosed herein using an enrichment and expansion process utilizing paramagnetic artificial antigen presenting cells (aAPCs) and a cocktail of recombinant T cell growth factors.

[0044] According to the present disclosure, central memory T cells (T CM T cells) are defined in this article as CD62L+ and CD45RA-. This memory subset is usually found in lymph nodes and peripheral circulation. Effector memory T cells (T EM TEMRA stands for terminally differentiated effector memory cells (T cells) that re-express CD45RA. emra ). These cells have no ability to divide and are CD62L- and CD45RA+.

[0045] T central memory cells (T CM ) show the ability to self-renew and, according to embodiments of the present invention, is also important for obtaining a long lifespan effect. EM The cells also have some self-renewal capacity and strongly express genes that are essential for cytotoxic functions. EMRA The cells also provided robust cytotoxic functions but did not display the ability to self-renew.

[0046] The composition of various embodiments comprises essentially T SCM , T CM and T EM In some embodiments, the cells comprise at least about 75%, at least about 80%, or at least about 90% of the memory phenotype.

[0047] In various embodiments, the T cells in the composition are at least about 30% central memory cells and effector memory cells, or at least about 40% central memory cells or effector memory cells, or at least about 50% central memory T cells or effector memory T cells, or in some embodiments at least about 70% central memory cells or effector memory cells, or at least about 80% central memory T cells or effector memory T cells, or at least about 90% central memory T cells or effector memory T cells.

[0048] In some embodiments, the cell composition comprises less than about 20% terminally differentiated memory T cells (e.g., T EMRAIn some embodiments, the CD8+ T cells contain no more than about 30% of naive cells, or in some embodiments, no more than about 15% of naive cells, or no more than about 10% of naive cells, or no more than about 5% of naive cells, or no more than about 4% of naive cells, or no more than about 3% of naive cells, or no more than about 2% of naive cells, or no more than about 1.5% of naive cells, or no more than about 1% of naive cells.

[0049] In various embodiments, the CD8+ T cells contain about 1% to about 100% T memory stem cells, or in some embodiments, about 1% to about 50% T memory stem cells, or in some embodiments, about 1% to about 25% T memory stem cells, or about 5% to about 25% T memory stem cells, or about 5% to about 15% T memory stem cells (i.e., naive, T SCM , T CM , T EM , T emra The total number of cells is 100%)

[0050] In some embodiments, T SCM and T CM The cells comprise between about 30% and about 80% of the memory phenotype, or in some embodiments, between about 40% and about 80% of the memory phenotype, or in some embodiments, between about 40% and about 70% of the memory phenotype.

[0051] In various embodiments, the T cells specific for the target antigen are at least about 30% of the central memory cells and effector memory cells, or at least about 40% of the central memory cells or effector memory cells, or at least about 50% of the central memory T cells or effector memory T cells, or in some embodiments at least about 70% of the central memory cells or effector memory cells, or at least about 80% of the central memory T cells or effector memory T cells, or at least about 90% of the central memory T cells or effector memory T cells. In some embodiments, these memory cells are central memory cells and effector memory cells of about 10:90 to about 90:10. In some embodiments, these memory cells are central memory cells and effector memory cells of about 25:75 to about 75:25. In some embodiments, the memory T cells are central memory cells and effector memory T cells of about 40:60 to about 60:40. T cells specific for one or more target antigens are less than about 20% of terminally differentiated memory T cells (e.g., TEMRA cells), or less than about 10% or less than about 5% or less than about 4% of terminally differentiated memory T cells. In various embodiments, T cells specific for target antigens contain no more than about 30% of initial cells, or in some embodiments no more than about 20% of initial cells, or in some embodiments no more than about 15% of initial cells, or no more than about 10% of initial cells, or no more than about 5% of initial cells, or no more than about 2% or 1.5% or 1% of initial cells. In various embodiments, antigen-specific T cells contain about 1% to about 100% of T memory stem cells, or in some embodiments, about 1% to about 50% of T memory stem cells, or in some embodiments, about 5% to about 25% of T memory stem cells or about 5% to about 15% of T memory stem cells. These memory T cells can be constructed by enrichment and expansion processes using paramagnetic artificial antigen presenting cells (aAPCs). T cells containing mainly T cells can be produced. SCM The T cells can be further isolated or enriched using known techniques including magnetic enrichment or cell sorting. SCM cell.

[0052] In various embodiments, the cell composition is at least 90% T cells, or at least 95% T cells, or at least 98% or at least 99% T cells. For the purposes of the present disclosure, T cells are characterized by CD3+ cells. T cells are generally CD8+ or CD4-. As used herein, unless otherwise indicated, the terms "CD8+" and "CD4-" are interchangeable. For example, the isolated cell composition may be characterized by having less than about 10% or less than about 5% CD4+ T cells, or in some embodiments, less than about 2%, less than about 1.5%, or less than about 1% CD4+ T cells. When CD8+ T cells are expanded ex vivo, CD4+ cells have a tendency to overgrow CD8+ cells and compete for growth signals, and exogenous CD4+ T cells are not necessary for a robust and durable response after adoptive transfer.

[0053] The presence of polyfunctional CD4+ and CD8+ T cells has been described to be associated with response to cancer vaccine therapy using peptide neoantigens. Ott PA et al., An immunogenic personal neoantigen vaccine for patients with melanoma , Nature 547(7662): 217-221 (2017). CD4+ and CD8+ T cells are further described as being important for mediating tumor cell destruction. See Tran E, Cancer immunotherapy based on mutation- specifc CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014); Sahin u et al., Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , Nature 547(7662): 222-226(2017). With respect to the present disclosure, it is believed that the adoptive cell composition need only provide a large number of antigen-specific CD8+ T cells, particularly when the phenotype can support a documented and sustained response, and particularly when the antigen-specific CD8+ T cells are provided in sufficient numbers.

[0054] In various embodiments, the cell composition is substantially CD28+. For example, in various embodiments, the cell composition is at least about 25%, or at least about 50%, or at least about 75%, or at least about 90% CD28+.

[0055] In various embodiments, antigen-specific T cells show a multifunctional phenotype after activation. For example, after activation, T cells are positive for two or more of the following: IL-2 as a marker of proliferation and memory; Activation of other T cells and induction of memory and upregulated IFN-γ production of MHC; Production of proinflammatory marker TNF-α; and intracellular staining of CD107A as a marker of granzyme release and cytotoxic activity. In various embodiments, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% of antigen-specific T cells show at least three of these markers. In various embodiments, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or at least 80% of antigen-specific T cells show at least four of these markers. In some embodiments, multifunctionality is assessed or quantified using a target killing assay that assesses the ability of CD8+ cytotoxic T cells to lyse target cells presenting the target antigen complexed with MHC.

[0056] In various embodiments, the cell composition further comprises γδT cells. γδT cells have a unique T cell receptor (TCR) on their surface. Compared to αβT cells, γδT cells have a TCR composed of one γ chain and one δ chain. It is believed that γδT cells do not require antigen processing and major histocompatibility complex (MHC) presentation of peptide epitopes for activation. γδT cells may play a role in recognizing lipid antigens and phosphoantigens, and may play a role in antiviral and antitumor protection. See Kalyan and Kabelitz, Defining the nature of human γδT cells: a biographical sketch of the highly empathetic , Cellular & Molecular Immunology (2013) 10, 21-29. γδT cells can provide help to CD8+ cells by releasing cytokines, for example, contributing to the activation, proliferation and differentiation of CD8+ cells. In addition, the clinical significance of γδT cells in the context of hematopoietic stem cell transplantation (HSCT) has been observed, and in particular, higher frequencies of γδT cells after transplantation are associated with favorable outcomes. See Berglund et al., Expansion of Gammadelta T cells from Cord Blood: A Therapeutic Possibili ty . Stem Cells International Vol. 2018.

[0057] In various embodiments, the cell composition comprises at least about 2% of γδT cells or at least about 5% of γδT cells. In some embodiments, the cell composition comprises at least about 10% of γδT cells or at least about 20% of γδT cells. In some embodiments, the cell composition comprises at least about 25% of γδT cells, or at least about 30% or at least about 35% or at least about 40% of γδT cells or at least about 45% of γδT cells. In these embodiments, γδT cells may include one or both of Vδ1 and Vδ2 cells. In some embodiments, a portion of γδT cells are CD8+. In various embodiments, γδT cells are mainly CD28+.

[0058] Cell compositions according to various embodiments can be prepared by enriching CD8+ cells that are specific for one or more target antigens (e.g., tumor-associated antigens or virus-associated antigens). Even when the source lymphocytes are mainly naive cells, such cell populations can be rapidly expanded in culture to achieve the cell composition described herein. CD4+ cells can be depleted from lymphocytes (before or after antigen-specific enrichment) using CD4+ cell depletion microbeads.

[0059] Antigen-specific enrichment of CD8+ cells can be performed using paramagnetic beads to actively select cell populations, and due to the potent magnetic aggregation of T cell surface receptors, it can have the additional advantage of activating initial cells. For example, paramagnetic beads or nanoparticles may contain monomers or polymeric (e.g., dimerized) HLA ligands and co-stimulatory signals presenting peptide antigens, in some embodiments, such as agonists of CD28 (e.g., antibody agonists of CD28). Exemplary methods according to these embodiments are described in WO 2016 / 044530, PCT / US2017 / 22663, and US 10,908,939 (all incorporated herein by reference in their entirety).

[0060] In some embodiments, CD28+ cells are also enriched, which can be carried out simultaneously with antigen-specific enrichment.CD28 is expressed on T cells and is a co-stimulatory signal required for T cell activation and survival.CD28 is the only B7 receptor constitutively expressed on naive T cells.The combination of TCR of naive T cells with MHC-antigen complexes in the absence of CD28 co-stimulation can obtain anergic T cells.In some embodiments, CD28+ cells are not enriched, but CD28 agonists are added in a soluble form during the enrichment process, or in a form conjugated with non-paramagnetic beads.In some embodiments, CD28 (in a conjugated form or a non-conjugated form) is added to cells after antigen-specific enrichment, with the purpose of activating cells for the expansion phase.

[0061] In various embodiments, T cells specific for target antigens (e.g., by virtue of peptides displayed by aAPC or pAPC) are specific for 1 to about 100 target antigens, or 1 to about 75 target antigens, or 1 to about 50 target antigens, or 1 to about 25 target antigens, or 1 to about 20 target antigens, or 1 to about 15 target antigens, or 1 to 10 target antigens, or 1 to 5 target antigens. In various embodiments, there are at least 3 or at least 4 or at least 5 target antigens. In some embodiments, different target antigens may include overlapping peptide epitopes. T cells specific for these peptide antigens can be enriched and amplified in batches, thereby allowing rapid, parallel production of cell compositions. In some embodiments, the composition contains T cells specific for 5 to 15 or 5 to 10 peptide antigens. T cell specificity for target peptide antigens in the composition is defined by MHC multimer staining (e.g., dimer or tetramer staining) as is well known in the art.

[0062] For example, a mixture of nano-aAPCs, each of which can present a different unique target antigen, can be used to simultaneously enrich T cells for multiple antigens. For example, T cells specific for 2 to 10 antigens can be simultaneously enriched from a lymphocyte source. In the embodiment, many different batches of nano-aAPCs (each carrying a different MHC peptide) will be combined and used to simultaneously enrich T cells for each antigen of interest. The resulting T cell pools will be activated against each of these antigens and amplified together in culture. These antigens may be associated with a single therapeutic intervention; for example, multiple antigens present on a single tumor or malignant cell.

[0063] The target peptide antigen is typically suitable for presentation by a complex of an HLA-A, B or C molecule, and in some embodiments is suitable for presentation by a complex of an HLA-A2 molecule.

[0064] In various embodiments, the target peptide antigen is a tumor or cancer associated antigen, including a tumor-derived antigen or a tumor-specific antigen. T cells specific for tumor-associated antigens are often very rare and in many cases undetectable in the peripheral blood of healthy individuals. Further, the cells are often of a naive phenotype, particularly when donor T lymphocytes are used. See Quintarelli et al., Cytotoxic T lymphocytes directed to the preferentially expressed antigens of melanoma(PRAME)target chronic myeloid leukemia. Blood 2008;112:1876-1885. This is a distinction often observed between virus-specific T cells and tumor antigen-specific T cells.

[0065] "Tumor-associated antigens" or "cancer-specific antigens" include unique tumor or cancer antigens that are specifically expressed by the tumor or malignant cells from which they originate, shared tumor antigens (carcinoembryonic antigens) that are expressed in many tumors but not in normal adult tissues, and tissue-specific antigens that are also expressed by normal tissues from which tumors arise. Tumor-associated antigens can be, for example, embryonic antigens, antigens with abnormal post-translational modifications, differentiation antigens, products of mutant oncogenes or tumor suppressor genes, fusion proteins, or oncogenic viral proteins.

[0066] In some embodiments, the target peptide antigens include one or more antigens associated with or derived from a blood cancer, such as leukemia, lymphoma, or myeloma. For example, the hematological malignancy may be acute myeloid leukemia, chronic myeloid leukemia, childhood acute leukemia, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, malignant cutaneous T cells, mycosis fungoides, non-MF cutaneous T cell lymphoma, lymphomatoid papulosis, and T cell-rich cutaneous lymphoid hyperplasia. In other embodiments, the target peptide antigens include one or more antigens associated with or derived from solid tumors, including melanoma, colon cancer, duodenal cancer, prostate cancer, breast cancer, ovarian cancer, ductal carcinoma, liver cancer, pancreatic cancer, renal cancer, endometrial cancer, testicular cancer, gastric cancer, oral mucosal dysplasia, polyposis, head and neck cancer, invasive oral cancer, non-small cell lung cancer, small cell lung cancer, mesothelioma, transitional and squamous cell urethral cancer, brain cancer, neuroblastoma and glioma.

[0067] A variety of tumor-associated antigens are known in the art. Carcinoembryonic and fetal antigens include carcinoembryonic antigen and alpha-fetoprotein (usually highly expressed only in developing embryos, but often highly expressed by tumors of the liver and colon, respectively), MAGE-1 and MAGE-3 (expressed in melanoma, breast cancer, and glioma), placental alkaline phosphatase sialyl-Lewis X (expressed in adenocarcinoma), CA-125 and CA-19 (expressed in gastrointestinal tumors, liver tumors, and gynecological tumors), TAG-72 (expressed in colorectal tumors), epithelial glycoprotein 2 (expressed in many cancers), pancreatic carcinoembryonic antigen, 5T4 (expressed in gastric cancer), alpha-fetoprotein receptor (expressed in a variety of tumor types (especially breast tumors)) and M2A (expressed in germ cell neoplasia).

[0068] Tumor-associated differentiation antigens include tyrosinase (expressed in melanoma) and specific surface immunoglobulins (expressed in lymphoma).

[0069] Mutated oncogenes or tumor suppressor gene products include Ras and p53 (both expressed in many tumor types), Her-2 / neu (expressed in breast and gynecological cancers), EGF-R, estrogen receptor, progesterone receptor, retinoblastoma gene products, myc (associated with lung cancer), ras, p53, non-mutant associated with breast tumors, MAGE-1 and MAGE-3 (associated with melanoma, lung cancer and other cancers). Fusion proteins include BCR-ABL, which is expressed in chronic myeloid leukemia. Oncogenic viral proteins include HPV16, E6 and E7 types found in cervical cancer.

[0070] Tissue-specific antigens include melanotransferrin and MUC1 (expressed in pancreatic and breast cancer); CD10 (formerly known as common acute lymphoblastic leukemia antigen or CALLA) or surface immunoglobulin (expressed in B-cell leukemias and lymphomas); IL-2 receptor, T-cell receptor, CD45R, alpha chain of CD4+ / CD8+ (expressed in T-cell leukemias and lymphomas); prostate-specific antigen and prostatic acid phosphatase (expressed in prostate cancer); GP100, MelanA / Mart-1, tyrosinase, gp75 / brown, BAGE, and S-100 (expressed in melanoma); cytokeratins (expressed in various carcinomas); and CD19, CD20, and CD37 (expressed in lymphomas).

[0071] Tumor-associated antigens also include altered glycolipid and glycoprotein antigens, such as neuraminic acid-containing glycosphingolipids (e.g., GM2 and GD2, expressed in melanoma and some brain tumors); blood group antigens, particularly T and sialylated Tn antigens, which may be aberrantly expressed in cancer; and mucins, such as CA-125 and CA-19-9 (expressed on ovarian cancer) or hypoglycosylated MUC-1 (expressed on breast and pancreatic cancer).

[0072] For example, in some embodiments, one or more target antigens are associated with bladder cancer, such as one or more of NY-ESO-1, MAGE-A10, and MUC-1 antigens. In some embodiments, one or more target antigens are associated with brain cancer and may include one or more of NY-ESO-1, survivin, and CMV antigens. In some embodiments, one or more target antigens are associated with breast cancer and may include one or more of MUC-1, survivin, WT-1, HER-2, and CEA antigens. In some embodiments, one or more target antigens are associated with cervical cancer and may include HPV antigens. In some embodiments, one or more target antigens are associated with colorectal cancer and may include one or more of NY-ESO-1, survivin, WT-1, MUC-1, and CEA antigens. In some embodiments, one or more target antigens are associated with esophageal cancer and may include NY-ESO-1 antigens. In some embodiments, one or more target antigens may be associated with head and neck cancer and may include HPV antigens. In some embodiments, the target antigen is associated with kidney cancer or liver cancer and may include NY-ESO-1 antigens. In some embodiments, the target antigen is associated with lung cancer and may include one or more of NY-ESO-1, survivin, WT-1, MAGE-A10, and MUC-1 antigens. In some embodiments, one or more target antigens are associated with melanoma and may include one or more of NY-ESO-1, survivin, MAGE-A10, MART-1, and GP-100. In some embodiments, one or more peptide antigens are associated with ovarian cancer and may include one or more of NY-ESO-1, WT-1, and mesothelin antigens. In some embodiments, one or more target antigens are associated with prostate cancer and may include one or more of survivin, hTERT, PSA, PAP, and PSMA antigens. In some embodiments, the target antigen is associated with sarcoma and may include NY-ESO-1 antigen. In some embodiments, one or more target antigens are associated with lymphoma and may include EBV antigens. In some embodiments, one or more target antigens are associated with multiple myeloma and may include one or more of NY-ESO-1, WT-1, XBP1-US, XBP1-SP, CD138, CS1 (SLAMF7), and SOX2 antigens. In some embodiments, the target antigen associated with multiple myeloma is two or more (or three, four, five, or six) of the peptide antigens disclosed in US 9,096,681, which is hereby incorporated by reference in its entirety. Exemplary peptides comprising antigenic epitopes include XBP1 unspliced ​​(UN) 185-193 、XBP1-US 184-192 , XBP1 spliced ​​(SP) 223-231 、XBP1-SP367-375 、CD138 265-273 、CD138 260-268 ,CS1 240-248 ,CS1 239-247 ,NY-ESO1 157-165A and SOX2 118-127 In some embodiments, the target antigen comprises NY-ESO-1, WT-1, SOX-2, CD138, and CS1. In some embodiments, the target antigen comprises NY-ESO-1, WT-1, SOX-2, CD138, CS1, and XBP1-US and / or XBP1-SP. In some embodiments, the peptide antigen comprises NY-ESO-1, WT-1, and SOX-2. See Table 2.

[0073] In some embodiments, one or more target antigens are associated with acute myeloid leukemia or myelodysplastic syndrome, and may include one or more (including 1, 2, 3, 4, or 5) of survivin, WT-1, PRAME, RHAMM, PR3, and cyclin A1 antigens. In some embodiments, the target antigens include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of the target antigens from Table 1 below.

[0074] Table 1: Exemplary AML target peptide antigens

[0075]

[0076]

[0077] In some embodiments, one or more target antigens may include

[0078] One or more of XBP1-US, XBP1-SP, CD138, CS1, NY-ESO1, SOX2, EBV, influenza, CMV, RHAMM, PR3, Mart-1 / Melan A, gp100, CMVpp65, and influenza matrix protein M1 antigens. In some embodiments, the target antigens include at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 target antigens from Table 2 below, which can be used to target multiple myeloma, melanoma, or various viral or infectious diseases.

[0079] Table 2: Exemplary target peptide antigens

[0080]

[0081]

[0082]

[0083] In some embodiments, one or more target peptide antigens are neoantigens. For example, in some embodiments, neoantigens specific to the patient are identified and synthesized for loading aAPC. In some embodiments, 3 to 10 neoantigens are identified by genetic analysis of the patient's malignant tumor (e.g., by nucleic acid sequencing of malignant cells) and then by predictive bioinformatics. In some embodiments, the antigen is a natural, non-mutated cancer antigen, many of which are known.

[0084] In various embodiments, at least one target peptide antigen is recognized by low frequency precursor T cells. According to these embodiments, the present invention enables these cells to be rapidly activated and expanded for adoptive therapy.

[0085] In some embodiments, the target peptide antigen includes at least one antigen associated with or derived from a pathogen, such as a viral, bacterial, fungal or parasitic pathogen. For example, at least one peptide antigen may be associated with HIV, hepatitis (e.g., A, B, C or D) CMV, Epstein-Barr virus (EBV), influenza, herpes virus (e.g., HSV1 or 2 or varicella zoster) and adenovirus. For example, CMV is the most common viral pathogen found in organ transplant patients and is the main cause of morbidity and mortality in patients receiving bone marrow or peripheral blood stem cell transplants. This is due to the immunocompromised state of these patients, which allows latent viruses in seropositive patients to reactivate or opportunistic infections to occur in seronegative individuals. In these embodiments, patients may receive adoptive immunotherapy comprising T cells specific for pathogen antigens. The method may require the generation of virus-specific CTLs derived from patients or appropriate donors before the start of the transplantation operation.

[0086] In some embodiments, at least one target antigen is a pathogen-associated antigen, including antigens associated with protozoa, bacteria, fungi (unicellular and multicellular), viruses, prions, intracellular parasites, helminths, and other infectious agents.

[0087] Bacterial antigens include antigens of Gram-positive cocci, Gram-positive bacilli, Gram-negative bacteria, anaerobes, such as organisms of the families Actinomycetaceae, Bacillaceae, Bartonellaceae, Bordetellae, Captophagaceae, Corynebacteraceae, Enterobacteriaceae, Legionellaceae, Micrococcaceae, Mycobacteraceae, Nocardiaceae, Pasteurellaceae, Pseudomonadaceae, Spirochaetaceae, Vibrioaceae, and organisms of the genera Acinetobacter, Brucella, Campylobacter, Erysipelothrix, Ewingella, Francisella, Gardnerella, Helicobacter, Levinea, Listeria, Streptobacter, and Tropheryma.

[0088] Antigens of protozoan infectious agents include antigens of malarial plasmodia, Leishmania species, Trypanosoma species, and Schistosoma species.

[0089] Fungal antigens include antigens of Aspergillus, Blastomyces, Candida, Coccidioides, Cryptococcus, Histoplasma, Paracoccicioides, Sporothrix, organisms of the order Mucorales, organisms that cause choromycosis and mycetoma, and organisms of the genera Trichophyton, Microsporum, Epidermophyton, and Malassezia.

[0090] Viral peptide antigens include, but are not limited to, antigens of adenovirus, herpes simplex virus, papillomavirus, respiratory syncytial virus, poxvirus, HIV, influenza virus, EBV, hepatitis, and CMV. Particularly useful viral peptide antigens include HIV proteins, such as HIV gag protein (including but not limited to membrane anchor (MA) protein, core capsid (CA) protein, and nucleocapsid (NC) protein), HIV polymerase, influenza virus matrix (M1) protein, and influenza virus nucleocapsid (NP) protein, hepatitis B surface antigen (HBsAg), hepatitis B core protein (HBcAg), hepatitis E protein (HBeAg), hepatitis B DNA polymerase, hepatitis C antigen, and the like.

[0091] In some embodiments, the target peptide antigens include one or more tumor-associated antigens and one or more virus-associated antigens (e.g., CMV, EBV, influenza, or adenovirus) in order to provide an anti-tumor response while protecting against common pathogens that complicate recovery after HSCT.

[0092] Patients who have undergone HSCT are at particular risk for infectious diseases due to their immunocompromised state. The immunocompromised status of these patients allows for latent viral reactivation in seropositive patients or for opportunistic infections to occur in seronegative individuals. For example, post-transplant lymphoproliferative disease (PTLD) occurs in a significant proportion of transplant patients and is caused by infection with the Epstein-Barr virus (EBV). EBV infection is thought to be present in approximately 90% of the adult population in the United States. Active viral replication and infection are controlled by the immune system, but as with CMV, individuals who are immunocompromised by transplantation therapy lose control of their T-cell populations, which allows for viral reactivation. This represents a serious impediment to transplantation protocols. EBV may also be involved in tumor promotion in a variety of hematological and non-hematological cancers.

[0093] In other embodiments, the cell composition comprises T cells specific for tumor-associated antigens, wherein pathogen-associated T cells are provided as bystander cells. In particular, by enriching CD8+ T cells based on the use of HLA peptide complexes and anti-CD28 selection, bystander cells will be enriched and amplified, especially when using a mixture of T cell growth factors that can drive some non-specific amplification of these cells in the absence of antigen-specific activation. In these embodiments, although most of the composition is T cells specific for target peptides (e.g., 5% to 75%, or 10% to 50%), the remaining T cells provide some immune system reconstruction for common pathogens, which is particularly beneficial after transplantation. For example, the composition may include T cells specific for CMV, EBV, influenza, and adenovirus. In each case, pathogen-specific T cells can be present in 0.1% to about 4% of the composition.

[0094] In various embodiments, the present invention relates to a composition prepared by enriching and amplifying antigen-specific CD8+ T cells. Precursor T cells can be obtained from patients or from suitable HLA-matched donors. Source T cells can be fresh samples or frozen samples. Precursor T cells can be obtained from many sources comprising WBC, including peripheral blood mononuclear cells (PBMC), bone marrow, lymph node tissue, spleen tissue, buffy coat fractions and tumors. In some embodiments, precursor T cells are obtained from blood units collected from subjects using any number of techniques known to those skilled in the art or technicians. For example, precursor T cells from individual circulating blood can be obtained by single collection or leukocyte single collection. Single collection products usually contain lymphocytes, including T cells and precursor T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes and platelets. Leukocyte single collection is a laboratory procedure for separating leukocytes from a blood sample.

[0095] The cells collected by apheresis can be washed to remove plasma components and the cells are placed in an appropriate buffer or culture medium for subsequent processing steps. The washing steps can be accomplished by methods known to those skilled in the art, such as by using a semi-automatic "flow-through" centrifuge. After washing, the cells can be resuspended in various biocompatible buffers, such as PBS without calcium or magnesium. Alternatively, the undesired components of the apheresis sample can be removed and the cells can be directly resuspended in culture medium.

[0096] If necessary, the monocytes may be depleted by lysing the erythrocytes (e.g., by PERCOLL TM Gradient centrifugation was used to separate precursor T cells from peripheral blood lymphocytes.

[0097] In certain embodiments, leukocytes are collected by leukapheresis, and CD8+ T cells can then be enriched, for example, by depleting CD4+ cells and / or positively enriching CD8+ cells in the sample. In some embodiments, other cell types, such as NK cells, are depleted. CD8-enriched cells can then be further enriched for antigen-specific T cells.

[0098] In various embodiments, a sample containing immune cells (e.g., CD8+ T cells) is contacted with an artificial antigen presenting cell (aAPC) having magnetic properties. Paramagnetic materials have a small positive magnetic susceptibility to a magnetic field. These materials are attracted to the magnetic field, and when the external field is removed, the material does not retain its magnetism. Exemplary paramagnetic materials include, but are not limited to, magnesium, molybdenum, lithium, tantalum, and iron oxides. Paramagnetic beads suitable for magnetic enrichment are commercially available (DYNABEADS TM ,MACSMICROBEADS TM , Miltenyi Biotec). In some embodiments, the aAPC particles are dextran iron beads (e.g., dextran-coated iron oxide beads).

[0099] Antigen presenting complex comprises antigen binding groove, and is generally MHC class I, which can be connected or bolted to provide dimeric or polymeric MHC. In some embodiments, the MHC is monomeric, but their close association on nanoparticles is sufficient for affinity and activation. In some embodiments, the MHC is dimeric. Dimeric MHC class I ligands can be constructed by fusion with immunoglobulin heavy chain sequences, and the immunoglobulin heavy chain sequences are then associated (associated with related light chains or not associated with related light chains) through one or more disulfide bonds. MHC polymers can be produced by direct bolting via peptides or chemical linkers, or can be formed by associating with streptavidin via biotin moieties. In some embodiments, the antigen presenting complex is an MHC class I complex involving fusion with immunoglobulin sequences.

[0100] U.S. Patent No. 6,268,411 (which is incorporated herein by reference in its entirety) describes MHC class I molecule complexes with immunoglobulin sequences. These MHC class I molecule complexes can be formed in a conformationally complete manner at the end of an immunoglobulin heavy chain. The MHC class I molecule complex bound to an antigenic peptide can stably bind to an antigen-specific lymphocyte receptor (e.g., a T cell receptor). In various embodiments, the immunoglobulin heavy chain sequence is not full-length, but comprises an Ig hinge region and one or more of the CH1, CH2, and / or CH3 domains. The Ig sequence may or may not comprise a variable region, but in the presence of a variable region sequence, the variable region may be complete or partial. The complex may also comprise an immunoglobulin light chain. As described in WO 2016 / 105542 (which is incorporated herein by reference in its entirety), an MHC class I ligand (e.g., HLA-Ig) lacking a variable chain sequence (and lacking any light chain) is employed in a site-specific conjugated manner with particles.

[0101] Exemplary MHC class I molecule complexes include at least two fusion proteins. The first fusion protein includes a first MHC class I alpha chain and a first immunoglobulin heavy chain (or a portion thereof including a hinge region), and the second fusion protein includes a second MHC class I alpha chain and a second immunoglobulin heavy chain (or a portion thereof including a hinge region). The first and second immunoglobulin heavy chains combine to form an MHC class I molecule complex, which includes two MHC class I peptide binding grooves. The immunoglobulin heavy chain may be a heavy chain of IgM, IgD, IgG1, IgG3, IgG2p, IgG2α, IgG4, IgE or IgA. In some embodiments, an IgG heavy chain is used to form an MHC class I molecule complex. If a multivalent MHC class I molecule complex is desired, an IgM or IgG heavy chain may be used to provide a pentavalent or tetravalent molecule, respectively.

[0102] Exemplary class I molecules include HLA-A, HLA-B, HLA-C, HLA-E, and these molecules can be used alone or in any combination. In some embodiments, the antigen presenting complex is an HLA-A2 ligand. The term MHC as used herein can be replaced with HLA in each example.

[0103] The immunoglobulin sequences in some embodiments are humanized monoclonal antibody sequences.

[0104] aAPC may contain "signal 2", such as an anti-CD28 ligand. Signal 2 is generally a T cell that affects a molecule, i.e., a molecule that has a biological effect on a precursor T cell or an antigen-specific T cell. In certain embodiments, signal 2 is a T cell co-stimulatory molecule. T cell co-stimulatory molecules help activate antigen-specific T cells. Such molecules include, but are not limited to, molecules that specifically bind to CD28 (including antibodies), CD80 (B7-1), CD86 (B7-2), B7-H3, 4-1BB, 4-1BBL, CD27, CD30, CD134 (OX-40L), B7h (B7RP-1), CD40, LIGHT, antibodies that specifically bind to HVEM, antibodies that specifically bind to CD40L, and antibodies that specifically bind to OX40. In some embodiments, the co-stimulatory molecule (signal 2) is an antibody (e.g., a monoclonal antibody) or a portion thereof, such as F(ab')2, Fab, scFv, or a single-chain antibody or other antigen-binding fragment. In some embodiments, the antibody is a humanized monoclonal antibody or a portion thereof having antigen binding activity, or is a fully human antibody or a portion thereof having antigen binding activity.

[0105] Combinations of co-stimulatory ligands that can be used (on the same or different nanoparticles) include anti-CD28 / anti-CD27 and anti-CD28 / anti-41BB. The ratio of these co-stimulatory ligands can be changed to affect expansion.

[0106] Exemplary Signal 1 and Signal 2 ligands are described in WO 2014 / 209868, which describes ligands having free sulfhydryl groups (eg, unpaired cysteines) such that the constant region can be coupled to a nanoparticle carrier with appropriate chemical functionalities.

[0107] Adhesion molecules useful for nano-aAPCs can be used to mediate the adhesion of nano-aAPCs to T cells or to T cell precursors. Useful adhesion molecules include, for example, ICAM-1 and LFA-3.

[0108] In some embodiments, signal 1 is provided by a peptide-HLA-A2 complex and signal 2 is provided by B7.1-Ig or anti-CD28. An exemplary anti-CD28 monoclonal antibody is 9.3 mAb (Tan et al., J. Exp. Med. 1993 177: 165), which in certain embodiments may be humanized and / or conjugated to beads in the form of a complete intact antibody or an antigen-binding fragment thereof.

[0109] Magnetic activation can occur for 2 minutes to 5 hours, or 5 minutes to 2 hours, followed by expansion in culture for at least 5 days, and in some embodiments up to 2 weeks or up to 3 weeks. In some embodiments, magnetic activation occurs for at least 2 minutes, but less than 30 minutes or less than 15 minutes (e.g., about 5 or 10 minutes). The resulting CD8+ T cells can be phenotypically characterized to confirm that the T memory stem cells (T scm ) and the presence of high central and effector memory phenotypes.

[0110] Some embodiments use T cell growth factors that affect the proliferation and / or differentiation of T cells during expansion. Examples of T cell growth factors include cytokines (e.g., interleukins, interferons) and superantigens. If necessary, cytokines may be present in a molecular complex comprising a fusion protein, or may be wrapped by aAPC, or provided in a soluble form. Particularly useful cytokines include MIP-1β, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, IL-21, IFN-γ and CXCL10. In some embodiments, growth factors include 3, 4, 5 or 6 species from MIP-1β, IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IL-15, IL-21 and INF-γ. In these or other embodiments, the cells are expanded in culture in the presence of cytokines including one, two, or three cytokines selected from MIP-1β, IL-1β, IL-6 and IL-10. In some embodiments, the cells are not cultured in the presence of IL-7 and / or IL-21 and / or IL- 15. The cells can be expanded in culture for 1 to 4 weeks, such as about 2 weeks (about 14 days) or about 3 weeks.

[0111] In some embodiments, the cells are expanded in culture in the presence of 4 to 8 cytokines to achieve a balance between T cell expansion (including antigen-specific T cell expansion), activation and memory phenotype. In some embodiments, the cells are expanded in the presence of IL-4. In some embodiments, the cells are expanded in the presence of IL-4 and IL-6. In some embodiments, the cells are not expanded in the presence of IL-4 and IL-1β. In some embodiments, the cells are expanded in the presence of IL-4, IL-6 and IL-1β. In some embodiments, the cells are expanded in the presence of IL-2, IL-4 and IL-6. In some embodiments, the cells are expanded in the presence of IL-2, IL-4, IL-6, INF-γ and IL-1β. In some embodiments, the cells are further expanded in the presence of IL-10. In various embodiments, these cytokines are used in combination with artificial or natural antigen presenting cells to expand antigen-specific T cells.

[0112] In some embodiments, the growth factor consists of or consists essentially of IL-2, IL-4, IL-6, INF-γ, IL-1β, and optionally IL-10.

[0113] In some embodiments, IL-2 is present at 10 to 200 international units (IU) / ml, such as about 20 to about 100 IU / ml, or about 20 to about 60 IU / ml at the start of the culture. In some embodiments, IL-2 is present at about 30 to about 50 IU / ml (e.g., about 40 IU / ml) at the start of the culture. IL-2 IU (86 / 500 NIBSC) can be measured using a proliferation assay (e.g., using a CTLL-2 cell line), such as, for example, Gearing and Bird (1987) in Lymphokines and Interferons,A Practical Approach . Clemens, MJ et al. (eds.): IRL Press. 295. In some embodiments, IL-2 is present at about 2 to about 25 ng / ml, or about 2 to about 15 ng / ml, such as about 5 to about 15 ng / ml at the start of the culture.

[0114] In these or separate embodiments, IL-4 is present at 0.2 to 25 international units (IU) / ml, such as about 0.5 to about 10 IU / ml, or about 0.5 to about 5 IU / ml at the start of the culture. In some embodiments, IL-4 is present at about 1 IU / ml at the start of the culture. IL-4 IU (88 / 656 NIBSC) can be defined using a proliferation assay (e.g., using the TF-1 cell line), such as, for example, Kitamura T. et al. (1991) IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line, TF- 1 .Int.Immunol.3:571-577. In some embodiments, IL-4 is present at about 0.2 to about 2 ng / ml, such as about 0.2 to about 1 ng / ml (e.g., about 0.5 ng / ml) at the beginning of the culture.

[0115] In these or separate embodiments, IL-6 may be present at 10 to 200 international units (IU) / ml, e.g., about 25 to about 100 IU / ml, e.g., from 25 to 75 IU / ml at the start of the culture. In some embodiments, IL-6 is present at about 40 to about 60 IU / ml (e.g., about 50 IU / ml) at the start of the culture. IL-6 IU (89 / 548 NIBSC) can be defined using a proliferation assay (e.g., using a B9 cell line), as described, e.g., in Gaines-Das RE and Poole S. (1993) in The international standard for interleukin-6.Evaluation in an international collaborative studyJ. Immunol. Methods 160: 147-153. In some embodiments, IL-6 is present at about 0.2 to about 10 ng / ml, such as about 0.2 to about 5 ng / ml (e.g., about 0.2 to 1 ng / ml, or about 0.5 to 2 ng / ml) at the start of the culture.

[0116] In these or separate embodiments, interferon gamma (INF-γ) may be present at 10 to 200 international units (IU) / ml, such as about 20 to about 100 IU / ml, such as 20 to 60 IU / ml at the start of culture. In some embodiments, INF-γ is present at about 30 to about 50 IU / ml (e.g., about 40 IU / ml) at the start of culture. INF-γ IU (87 / 586 NIBSC) can be defined using an antiviral assay (e.g., using Hela cells infected with EMC), as described, for example, in Meager A. (1987) Lymphokines and interferons, a Practical Approach .Clemens, MJ et al. (eds.): IRL Press. 129. In some embodiments, INF-γ is present at about 0.5 to about 20 ng / ml, such as about 0.5 to about 10 ng / ml, or about 0.5 to about 5 ng / ml, or about 1 to about 10 ng / ml (e.g., 1 to 5 ng / ml) at the start of the culture.

[0117] IL-1β may be present at 5 to 100 international units (IU) / ml, such as about 10 to about 50 IU / ml, such as 10 to about 30 IU / ml at the start of the culture. In some embodiments, IL-1β is present at about 10 to about 20 IU / ml (e.g., about 15 IU / ml) at the start of the culture. IL-1β IU (86 / 680 NIBSC) can be defined using a proliferation assay (e.g., using D.10.G4.1 cells), such as, for example, by Poole, S. and Gaines-Das, RE (1991) The international standards for interleukin-1alpha and interleukin-1beta.Evaluation in an international collaborative study J. Immunol. Methods 142: 1-13. In some embodiments, IL-1β is present at about 0.1 to 5 ng / ml, or about 0.2 to about 5 ng / ml, such as about 0.2 to about 2 ng / ml or about 0.2 to about 1 ng / ml at the start of the culture.

[0118] In various embodiments, the cells are cultured in the presence of a growth factor mixture comprising IL-2, IL-4, IL-6, INF-γ and IL-1β or consisting of IL-2, IL-4, IL-6, INF-γ and IL-1β. In some embodiments, the relative activity of IL-2 and INF-γ (defined by the corresponding IU) is about 0.5:1 to about 1:0.5 (e.g., about 1:1). In these or independent embodiments, the relative activity of IL-2 and IL-6 (defined by the corresponding IU) is about 0.5:1 to 1:0.5. In these or independent embodiments, the relative activity of IL-1β relative to IL-2, IL-6 and / or IFN-γ (defined by the corresponding IU) is 1:4 to 1:2 (e.g., 1:3). In these or independent embodiments, the relative activity of IL-4 relative to IL-2, IL-6 and / or IFN-γ (defined by the corresponding IU) is 1:30 to 1:60. In these or separate embodiments, the relative activity of IL-4 relative to IL-1β (defined as corresponding IU) is from about 1 :5 to about 1 :25, such as from about 1 :10 to about 1 :20.

[0119] In some embodiments, the specific activity (IU) of each growth factor (IL-2, IL-4, IL-6, INF-γ, and IL-1β) at the start of culture can be expressed as a percentage when the total IU of all growth factors in the culture is considered to be 100%. For example, in some embodiments, the percentage of each growth factor in the culture can be as follows:

[0120] 20% to 40% IL-2 (e.g., 20 to 30% IL-2);

[0121] 0.5% to 5% IL-4 (e.g., 1 to 3% IL-4);

[0122] 25% to 50% IL-6 (e.g., 30 to 40% IL-6);

[0123] 20% to 40% IFN-γ (e.g., 20 to 30% IFN-γ); and

[0124] 5% to 20% IL-1β (eg, 5 to 15% IL-1β).

[0125] aAPC nanoparticles can be made of any material, and the material can be appropriately selected according to the desired magnetic properties, and can include, for example, metals such as alloys of iron, nickel, cobalt or rare earth metals. Paramagnetic materials also include magnesium, molybdenum, lithium, tantalum and iron oxides. Paramagnetic beads suitable for enriching materials (including cells) are commercially available and include dextran iron beads, such as dextran-coated iron oxide beads. In aspects of the present invention where magnetic properties are not required, nanoparticles can also be made of non-metallic or organic (e.g., polymer) materials, such as cellulose, ceramics, glass, nylon, polystyrene, rubber, plastic or latex. Exemplary materials for preparing nanoparticles are poly (lactic-glycolic acid) copolymers (PLGA) or PLA and copolymers thereof, which can be used in conjunction with these embodiments. Other materials including polymers and copolymers that can be used include materials described in PCT / US2014 / 25889 (which is incorporated herein by reference in its entirety).

[0126] In various embodiments, the size (e.g., mean diameter) of the particle is in the range of about 10 to about 500nm, or in the range of about 40 to about 400nm, or in the range of about 40nm to about 200nm. For magnetic aggregation, the size (mean diameter) of the preferred nanoparticles in some embodiments is in the range of 10 to 250nm, or 50 to 200nm, or 80 to 200nm, or 20 to 100nm. The receptor-ligand interaction at the cell-nanoparticle interface is not clear. However, nanoparticle binding and cell activation are sensitive to membrane spatial organization, which is particularly important in the T cell activation process, and magnetic fields can be used to manipulate the nanoparticles bound by clusters to improve activation. For example, T cell activation induces a continuously enhanced nanoscale TCR aggregation state, and nanoparticles are sensitive to this aggregation, while larger particles are not.

[0127] In addition, the interaction of nanoparticles with TCR clusters can be used to enhance receptor triggering. T cell activation is mediated by the aggregation of signal transduction proteins, in which "signal transduction clusters" span hundreds of nanometers, are initially formed at the edge of the T cell-APC contact site and migrate inward. As described herein, an external magnetic field can be used to enrich antigen-specific T cells (including rare initial cells) and to drive the aggregation of magnetic nano aAPCs bound to TCR, thereby resulting in TCR cluster aggregation and initial T cell activation enhancement. The magnetic field can apply a suitable strong force to paramagnetic particles, but is otherwise biologically inert, which makes them a powerful tool for controlling particle behavior. T cells bound to paramagnetic nano aAPCs are activated in the presence of an externally applied magnetic field. Nano aAPCs themselves are magnetized and attracted by nanoparticles near the field source and field, thereby inducing beads and thus inducing TCR aggregation to enhance aAPC-mediated activation.

[0128] Activation chemistry can be used to achieve specific stable connection of molecules to nanoparticle surfaces. There are various methods that can be used to connect proteins to functional groups. For example, in a two-step process, common cross-linking agent glutaraldehyde can be used to connect protein amine groups to aminated nanoparticle surfaces. The resulting connection bond is stable on hydrolysis. Other methods include using cross-linking agents containing N-hydroxysuccinimide (NHS) esters (which react with amines on proteins), cross-linking agents containing active halogens (which react with proteins containing amines, sulfhydryls or histidine), cross-linking agents containing epoxides (which react with amines or sulfhydryls), conjugation between maleimide groups and sulfhydryl groups, and the formation of protein aldehyde groups (which is carried out by oxidizing the side-joined sugar moieties with periodate, followed by reductive amination).

[0129] When used simultaneously on the same or different particles, the ratio of a specific ligand can be changed to increase the effectiveness of nanoparticles in antigen or co-stimulatory ligand presentation. For example, nanoparticles can be coupled with HLA-A2-Ig and anti-CD28 (or other signal 2 ligands) at a variety of ratios, such as about 30: 1, about 25: 1, about 20: 1, about 15: 1, about 10: 1, about 5: 1, about 3: 1, about 2: 1, about 1: 1, about 0.5: 1, about 0.3: 1, about 0.2: 1, about 0.1: 1 or about 0.03: 1. In some embodiments, the ratio is 2: 1 to 1: 2. The total amount of protein coupled to the carrier can be, for example, about 250 mg / ml, about 200 mg / ml, about 150 mg / ml, about 100 mg / ml, or about 50 mg / ml particles. Because effector functions such as cytokine release and growth have different requirements for signal 1 versus signal 2 than T cell activation and differentiation, these functions can be assayed separately.

[0130] In certain embodiments, the aAPC is a paramagnetic particle in the range of 50 to 150 nm, wherein the PDI (size distribution) is less than 0.2, or in some embodiments less than 0.1. The aAPC may have a surface charge of 0 to -10 mV, for example, about -2 to -6 mV. The aAPC may have 10 to 120 ligands per particle, for example, about 25 to about 100 ligands per particle, wherein the ligands are conjugated to the particles by free cysteines introduced in the Fc region of the immunoglobulin sequence. The particles may contain about a 1:1 ratio of HLA dimers: anti-CD28, which may be present on the same or different particle populations. The nanoparticles provide a robust expansion of homologous T cells while exhibiting no stimulation of non-homologous TCRs, even in the case of passive loading of peptide antigens. The particles are stable for at least two or three years in lyophilized form.

[0131] After enrichment and amplification, the antigen-specific T cell component of the sample will be at least about 5%, or at least about 10%, or at least about 15%, or at least about 20% or at least about 25% of the antigen-specific T cells. In addition, these T cells include T memory stem cells, and may also include central memory T cells and effector memory T cells. According to the original sample isolated from the patient, the antigen-specific T cells in various embodiments are expanded from about 100 times (in about 7 days) to about 10,000 times, for example, at least about 100 times, or at least about 200 times. After 2 weeks, the antigen-specific T cells are expanded by at least 1,000 times or at least about 2,000 times, at least about 3,000 times, at least about 4,000 times or at least about 5000 times in various embodiments. In some embodiments, the antigen-specific T cells are expanded by more than 5,000 times or more than 10,000 times after two weeks. After one or two weeks of expansion, at least about 10 6 or at least about 10 7 or at least about 10 8 or at least about 10 9 antigen-specific T cells.

[0132] Suitable incubation conditions (culture medium, temperature, etc.) include conditions for culturing T cells or T cell precursors, and conditions known in the art for inducing the formation of antigen-specific T cells using DCs or artificial antigen-presenting cells.

[0133] The cell composition can be administered to a patient by any appropriate route including intravenous infusion, intra-arterial administration, intralymphatic administration, and intratumoral administration.

[0134] In some embodiments, the patient receives or starts immunotherapy with one or more checkpoint inhibitors before receiving the cell composition by adoptive transfer (or optionally after receiving the cell composition by adoptive transfer). In various embodiments, one or more checkpoint inhibitors target one or more of CTLA-4 or PD-1 / PD-L1, which may include antibodies to such targets, such as monoclonal antibodies or portions thereof or humanized or fully humanized forms thereof. In some embodiments, the checkpoint inhibitor treatment comprises ipilimumab or pembrolizumab, or comparable monoclonal antibodies. In some embodiments, the patient has previously received PD1 blocking therapy and is refractory to the treatment or has only a partial response to the treatment. In such embodiments, the cell composition described herein may be optionally combined with a second round of immunotherapy (e.g., anti-CTLA4 or PD-1 blocking therapy) to restore a robust T cell response.

[0135] In some embodiments, the patient receives about 1 to 5 rounds of adoptive immunotherapy (e.g., one, two, three, four or five rounds of adoptive immunotherapy). In some embodiments, each administration of adoptive immunotherapy is performed simultaneously with a round of checkpoint inhibitor treatment or after a round of checkpoint inhibitor treatment (e.g., about 1 day to about 1 week after a round of checkpoint inhibitor treatment). In some embodiments, adoptive immunotherapy is provided about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days or about 1 week after administering a checkpoint inhibitor dose. In some embodiments, the patient receives only a single administration of the cell composition.

[0136] In some aspects, the present invention provides methods for personalized cancer immunotherapy by using aAPCs to identify antigens to which a patient will respond, and then administering appropriate peptide-loaded aAPCs to the patient, or subsequently enriching and expanding antigen-specific T cells ex vivo.

[0137] Whole genome sequencing has dramatically changed our understanding of cancer biology. Cancer sequencing has generated important data on the molecular processes involved in the development of many human cancers. Driver mutations have been identified in major genes involved in pathways regulating three major cellular processes: (1) cell fate; (2) cell survival; and (3) genome maintenance. Vogelstein et al., Science 339, 1546-58 (2013).

[0138] Whole genome sequencing also has the potential to revolutionize our approach to cancer immunotherapy. Sequencing data can provide information about shared as well as personalized targets for cancer immunotherapy. In principle, mutated proteins are foreign to the immune system and are putative tumor-specific antigens. In fact, sequencing efforts have defined hundreds, if not thousands, of potentially relevant immune targets. Limited studies have demonstrated that T cell responses against these new epitopes can be found in cancer patients or induced by cancer vaccines. However, the frequency of such responses against specific cancers and the extent to which such responses are shared between patients are unclear. A major reason for our limited understanding of tumor-specific immune responses is that the current pathways for validating potential immune-related targets are cumbersome and time-consuming.

[0139] Although central tolerance eliminates T cell responses to self-proteins, oncogenic mutations induce new epitopes against which T cell responses can be formed. The mutation catalog derived from whole exome sequencing provides a starting point for identifying such new epitopes. Using the HLA binding prediction algorithm (Srivastava, PLoS One 4, e6094 (2009)), it is predicted that each cancer may have up to 7 to 10 new epitopes. A similar approach predicts hundreds of tumor new epitopes. However, the accuracy of such algorithms in predicting T cell responses may be low, and it is estimated that only 10% of the predicted HLA binding epitopes are bound in the context of HLA (Lundegaard C, Immunology 130, 309-18 (2010)). Therefore, the predicted epitopes must be verified for whether there are T cell responses against these potential new epitopes.

[0140] In certain embodiments, the nano-aAPC system is used to screen for new epitopes that induce T cell responses in a variety of cancers or in a specific patient's cancer.Cancers can be genetically analyzed, for example, by whole exome sequencing.

[0141] A list of candidate peptides can be generated from overlapping nine amino acid windows in the mutant protein. All nine AA windows containing the mutant amino acid and 2 non-mutated "controls" for each protein will be selected. These candidate peptides will be computationally evaluated for MHC binding using a consensus of MHC binding prediction algorithms including Net MHC and the Stable Matrix Method (SMM). Nano-aAPC and MHC binding algorithms were developed primarily for HLA-A2 alleles. The sensitivity cutoff of the consensus prediction can be adjusted until a manageable number of mutation-containing peptides (approximately 500) and non-mutated control peptides (approximately 50) are identified.

[0142] In an exemplary embodiment, the cell composition comprises: at least 70%, at least 80%, or at least 90% CD8+ or CD4- T cells and less than 5% CD4+ T cells; and at least 5% T cells in a pharmaceutically acceptable carrier. SCM cells, wherein the CD8+ cells comprise at least 10 6 T cells specific for 1 to 10 target peptide antigens. Optionally, the CD8+ or CD4- T cells may include T cells specific for bacterial, viral, fungal and / or parasitic pathogens. In various embodiments, at least 30% of the CD8+ or CD4- T cells are T cells. SCM , central memory T cells and effector memory T cells, wherein less than 10% of the CD8+ or CD4- T cells are terminally differentiated T cells, and less than 10% of the CD8+ or CD4- cells are naive cells. In various embodiments, at least 50% of the CD8+ or CD4- T cells specific for the target peptide antigen are TSCM , central memory T cells and effector memory T cells. In some embodiments, the cell composition comprises about 5% to about 25% T memory stem cells (T scm ), or about 5% to about 20% of T memory stem cells.

[0143] In various embodiments, the cell composition further comprises γδT cells. For example, the cell composition may comprise at least about 2% of γδT cells or at least about 5% of γδT cells. In some embodiments, the cell composition comprises at least about 10% of γδT cells or at least about 20% of γδT cells. In some embodiments, the cell composition comprises at least about 25% of γδT cells, or at least about 30% or at least about 35% or at least about 40% of γδT cells. In these embodiments, γδT cells may include one or both of Vδ1 and Vδ2 cells. In some embodiments, γδT cells are mainly Vδ2 (e.g., at least about 60% or at least about 75%). In some embodiments, a portion of γδT cells are CD8+. In various embodiments, γδT cells are mainly CD28+.

[0144] In some embodiments, the cell composition further comprises a pharmaceutically acceptable carrier suitable for intravenous infusion and suitable as a cryoprotectant. An exemplary carrier is DMSO (e.g., about 10%). The cell composition can be provided in a unit vial or bag and stored frozen until use. A unit dose can contain about 5x10 5 About 5x10 6 In some embodiments, the volume of the composition is ≤100 ml (eg, 50 ml to 100 ml).

[0145] In some aspects, the invention provides methods of treating a patient suffering from cancer comprising administering to a patient in need thereof a cellular composition described herein.

[0146] In some embodiments, the patient has a hematological cancer, which in some embodiments relapses after allogeneic stem cell transplantation. In some embodiments, the patient has acute myeloid leukemia (AML) or myelodysplastic syndrome.

[0147] Other cancers that can be treated according to the present disclosure are included in cancers that have caused adverse immune responses or have a high recurrence rate in history. Exemplary cancers include various types of solid tumors, including cancers, sarcomas, and lymphomas. In various embodiments, the cancer is melanoma (including metastatic melanoma), colon cancer, duodenal cancer, prostate cancer, breast cancer, ovarian cancer, ductal carcinoma, liver cancer, pancreatic cancer, kidney cancer, endometrial cancer, testicular cancer, gastric cancer, oral mucosal dysplasia, polyposis, head and neck cancer, invasive oral cancer, non-small cell lung cancer, small cell lung cancer, mesothelioma, transitional and squamous cell urethral cancer, brain cancer, neuroblastoma, and glioma. In various embodiments, the cancer is Phase I, Phase II, Phase III, or Phase IV cancer. In some embodiments, the cancer is metastatic and / or recurrent, and / or unresectable.

[0148] In some embodiments, the patient is refractory to chemotherapy and / or checkpoint inhibitor therapy.

[0149] In some embodiments, the patient also receives low-dose cytokine therapy, which may improve persistence and in vivo responses.

[0150] In some embodiments, the cancer is a hematological malignancy, including leukemia, lymphoma or myeloma. For example, the hematological malignancy may be acute myeloid leukemia, chronic myeloid leukemia, childhood acute leukemia, non-Hodgkin's lymphoma, acute lymphocytic leukemia, chronic lymphocytic leukemia, myelodysplastic syndrome, malignant skin T cells, mycosis fungoides, non-MF skin T cell lymphoma, lymphomatoid papulosis and T cell-rich skin lymphoid hyperplasia. In an exemplary embodiment, the patient suffers from a hematological cancer, such as acute myeloid leukemia (AML) or myelodysplastic syndrome, and in some embodiments, the patient relapses after allogeneic stem cell transplantation. In some embodiments, the treatment does not induce GVHD.

[0151] In some embodiments, the patient has received lymphodepletion therapy, cytoreductive therapy, or immunomodulatory therapy (before administering cell therapy) in addition to allogeneic stem cell transplantation. In some embodiments, the cell therapy may be further provided with or without cytokine support after treatment.

[0152] In some embodiments, the patient suffers from an infectious disease or is at risk of an infectious disease. For example, a patient who has undergone HSCT is at a specific risk of an infectious disease due to an immunocompromised state. Infectious diseases that can be treated or prevented include infectious diseases caused by bacteria, viruses, prions, fungi, parasites, worms, etc. Such diseases include AIDS, hepatitis B / C, CMV infection, Epstein-Barr virus (EBV) infection, influenza, herpes virus infection (including herpes zoster) and adenovirus infection. For example, CMV is the most common viral pathogen found in organ transplant patients and is the main cause of morbidity and mortality in patients receiving bone marrow or peripheral blood stem cell transplantation. This is due to the immunocompromised state of these patients, which allows latent viruses in seropositive patients to reactivate or opportunistic infections to occur in seronegative individuals. In these embodiments, the patient can receive adoptive immunotherapy comprising T cells specific for pathogen antigens. The method may require the generation of virus-specific CTLs derived from patients or appropriate donors before the start of the transplantation operation.

[0153] PTLD occurs in a large proportion of transplant patients and is caused by infection with the Epstein-Barr virus (EBV). EBV infection is thought to be present in approximately 90% of the adult population in the United States. Active viral replication and infection are controlled by the immune system, but as with CMV, individuals who are immunocompromised by transplant therapy lose control of their T-cell populations, which allows viral reactivation. This represents a serious impediment to transplantation protocols. EBV may also be involved in tumor promotion in a variety of hematological and non-hematological cancers.

[0154] In other embodiments, the present invention provides a method for preparing a γδT cell colony. The method includes amplifying a T cell colony in the presence of two or more of IL-2, IL-4, IL-6, INF-γ and IL-1β. The T cell colony can be enriched with CD28+ enriched cells, for example, positive selection can be performed with beads or particles containing anti-CD28 (including aAPC as described herein). In some embodiments, the cell colony is CD4+ depleted or CD8+ selected. In various embodiments, the starting composition comprises less than about 20% or less than about 10% or less than about 8% or less than about 5% of γδT cells. In some embodiments, the source cells are from peripheral blood.

[0155] In various embodiments, the T cell population is expanded in the presence of IL-4, or in the presence of IL-4 and IL-6. In some embodiments, the cells are not expanded in the presence of IL-4 and IL-1β. In some embodiments, the cells are expanded in the presence of IL-4, IL-6 and IL-1β. In some embodiments, the cells are expanded in the presence of IL-2, IL-4 and IL-6. In some embodiments, the cells are expanded in the presence of IL-2, IL-4, IL-6, INF-γ and IL-1β. The expansion of cells in culture can be performed as described herein for 1-4 weeks. After the expansion period, the percentage of γδ cells may be between about 5% and about 60%, such as between about 10% and about 60%, or about 15% to about 60%, wherein the number of γδT cells can be expanded by at least about 100 or at least about 1000 or at least about 10,000 compared to the starting cell population.

[0156] γδT cells can be separated from other cells using known methods (such as FACS or magnetic cell sorting).γδT cells can be provided as cell compositions for adoptive transfer or research purposes, or alternatively can be engineered to express one or more heterologous genes, such as T cell receptors, which are optionally αβTCRs.In some embodiments, γδT cells are engineered to heterologously express chimeric antigen receptors (CARs).

[0157] Other aspects and embodiments of the invention will be apparent to those skilled in the art.

[0158] Example

[0159] To generate antigen-specific CD8+ T cells, e.g. Figure 2 As schematically shown in FIG, fresh PBMCs are obtained from a donor by leukocyte apheresis. The cells are depleted of CD4+ cells by negative selection with anti-CD4 microbeads. The resulting cells are co-incubated with paramagnetic nanoparticles (i.e., dextran-coated iron oxide nanoparticles or PLGA-PEG nanoparticles with a diameter in the range of about 80-200 nm) to enrich the resulting cells for antigen-specific T cells. Figure 1 As shown, the nanoparticles have dimeric HLA ligands (presenting target peptide antigens) conjugated to the surface, which can incorporate a variety of tumor-specific antigenic peptides. The dimeric HLA ligand contains two HLA-A2 domains containing a peptide binding groove, each of which is fused to the arm of the Ig hinge region. The dimeric HLA-Ig is co-expressed with β2 microglobulin. Dimeric HLA ligands (such as HLA-IgG4 hinge dimers) can be easily modified for a variety of HLA subtypes and provide direct engagement with target T cells. Co-stimulatory or inhibitory ligands (such as anti-CD28 monoclonal antibodies) are also conjugated to the nanoparticles, such as Figure 1 As shown. Co-stimulatory or inhibitory ligands provide specific instructions (e.g., activation, inhibition) to target T cells relative to the therapeutic goal to target T cells (i.e., naive T cells or memory T cells). Ligands and aAPC constructs are disclosed in WO 2016 / 044530 and WO 2016 / 105542, which are incorporated herein by reference in their entirety.

[0160] The cells are incubated in the presence of paramagnetic aAPC and then incubated for about 5 minutes in the presence of a magnetic field. Then, the cells bound to the particles are recovered and amplified in vitro for different durations (generally 1 to 2 weeks). Amplification is performed in the presence of growth factors. For a two-week culture period, growth factors are added on the 1st and 7th days. Cells are re-stimulated with nano-aAPC on the 7th day. Tumor-specific CD8+ T cells were observed to expand to therapeutic levels within two weeks of separation from donor cells. In some embodiments, the enrichment and amplification process can be performed in a closed automatic cell amplification system. Such a system can provide simple, scalable and cost-effective manufacturing, as well as consistent and rapid production of antigen-specific CD8+ T cells using different antigen peptide mixtures (i.e., derived from patients or donor PBMCs).

[0161] Table 3 shows the composition of cytokines used for expansion.

[0162] Table 3: Cytokines in the expansion phase

[0163]

[0164] Cell phenotypes using enrichment and expansion processes, including together with expansion phase cytokines, are disclosed in PCT / US2018 / 051971 (titled CELL COMPOSITIONS COMPRISING ANTIGEN-SPECIFIC T CELLS FOR ADOPTIVE THERAPY). PCT / US2018 / 051971 is hereby incorporated by reference in its entirety.

[0165] Using the disclosed methods to enrich and expand acute myeloid leukemia (AML)-specific T cells in Figure 3 Shown in. Figure 3 The left panel shows the effect of targeting T cells to the AML-specific antigen WT1. 37-45 、WTI 126-134 ,PRAME 425 , Cyclin A1 227-235 and cyclin A1 341-351 Total number of CD8+ T cells generated from fresh PBMCs from four healthy donors after ex vivo enrichment and expansion. Figure 3The graph on the right shows the total percentage of acute myeloid leukemia (AML) specific antigens after ex vivo enrichment and expansion of CD8+ T cells. Figure 3 The results in demonstrate that the proportion of AML-specific CD8+ T cells generated by the method of the present disclosure is significantly higher than that of cell compositions derived from other endogenous T cell therapies.

[0166] Then in Figure 4A and Figure 4B Targeting cell phenotypes, including naive T cells (T N )(CD62L+, CD45RA+), central memory T cells (T CM )(CD62L+, CD45RA-), effector memory T cells (T EM )(CD62L-, CD45RA-), effector memory RA+ T cells (T EMRA )(CD62L-, CD45RA+) and T memory stem cells (T SCM )(CD62L+, CD45RA+, CD95+) cells were characterized. More than 95% of AML-specific T cells enriched and expanded ex vivo from donor lymphocytes had a memory T cell phenotype. More than 60% of E+E-generated T cells had a T memory stem cell phenotype and a central memory T cell phenotype. In addition, Figure 4B As shown, the E+E system produced a consistent memory T cell phenotype across all donors. The E+E process also generated a large number of multiple myeloma-specific T memory stem cells from two different healthy donors, Leucopak. (See Figure 8 and Fig. 9A )exist Fig. 9A and Fig. 9B In the experiment, multiple myeloma-specific antigen T cells were enriched and expanded to approximately 1.6×10 based on hinge dimer staining. 9 CD8+ T cells.

[0167] Figure 5A and Figure 5B The results showed that AML-specific T cells enriched and expanded ex vivo had a highly polyfunctional phenotype, including intracellular staining for IL-2 (proliferation and memory), IFN-γ (activation of other T cells, memory, MHC upregulation), TNF-α (proinflammatory), and CD107A (granzyme release, cytotoxic activity). The vast majority of AML-specific T cells (i.e., approximately 62%) exhibited 3-4 effector functions upon nonspecific stimulation ( Figure 5A , top). Figure 5A In (bottom), the graph shows the percentage of T cells expressing IL-2, TNF-α, IFN-γ and CD107A. Figure 5AIn this experiment, T cells were generated by nonspecific stimulation of peptide-pulsed T2 cells. The results of this experiment showed that for most E+E-generated AML-specific CD8+ T cells, at least 3 or 4 cytokine effector functions were observed. Figure 5B In the figure, T cell-mediated tumor-specific killing of the AML cell line U266 at two effector to target (E:T) ratios of 10:1 (left bar) and 20:1 (right bar) from fresh PBMCs of healthy donors with AML-specific antigens is shown. The results of this experiment show that the CD8+ T cell composition generated by E+E from healthy donors has robust killing activity within a variety of E:T ratios.

[0168] Figure 6 Composed of four graphs comparing the specificity of Mart-1 specific T cells generated by the enrichment and expansion process disclosed herein between PBMCs derived from melanoma patients (top) and PBMCs derived from healthy donors (bottom). Regardless of the donor source, the enrichment and expansion process produces a consistent cell composition. The data in this experiment were generated from frozen PBMCs.

[0169] Figure 7 The results show that the AIMACT-based E+E process generates a TCR library that mimics the natural immune response, thereby providing robust adoptive therapy from a natural T cell pool that has undergone natural selection. The breadth of the polyclonal TCR library enables a natural and durable immune response.

[0170] Figure 8 The E+E process is shown to generate a large number of multiple myeloma antigen-specific T memory stem cells (TSCM) ((CD62L+, CD45RA+, CD95+). The figure shows the phenotype of multiple myeloma antigen-specific T cells before and after expansion from a healthy donor leucopak. Fig. 9A The phenotype of T cells from ex vivo batch enrichment and expansion of multiple myeloma antigen-specific T cells from healthy donor leucopak is shown. The figure shows that the E+E process produced a large number of antigen-specific CD8+ T cells (based on hinge dimer staining, about 1.6x10 9 CD8+ T cells), which include T memory stem cells (TSCM), central memory T cells (TCM) and effector memory T cells (TEM). Fig. 9B The phenotype of T cells enriched and expanded in vitro from multiple myeloma antigen-specific T cells of four different multiple myeloma patients is shown. The figure shows that the E+E process produces a large number of antigen-specific CD8+ T cells, including T memory stem cells (T SCM ), central memory T cells T CM and effector memory T cells (TEM ). These data indicate that PBMCs from clinical patients have the same phenotypic characteristics as PBMCs from donors, and notably, the E+E process can effectively generate a large number of antigen-specific CD8+ T cells, including T memory cells (e.g., T memory stem cells (TSCMs), central memory T cells TCMs, and effector memory T cells (TEMs)).

[0171] Fig.10 The generation of γδ T cells using the E+E process is shown. Vδ1 and Vδ2 TCR subtypes were observed. The clinical significance of γδ T cells in the context of hematopoietic stem cell transplantation (HSCT) has been reported, and in particular, higher frequencies of γδ T cells after transplantation are associated with favorable outcomes. See Berglund et al., Expansion of Gammadelta T cells from Cord Blood: A Therapeutic Possibility. Stem Cells International, Vol. 2018. Fig.11 As shown, the % of γδ T cells on day 14 varied, with a mean of about 15% to about 50% γδ T cells. The number of γδ T cells on day 14 was broadly correlated with the number of γδ T cells on day 0.

[0172] In the following experiments, the characteristics of the expanded T cells were evaluated in terms of identity, purity, phenotype and specificity. The summarized characteristics of the batches enriched with anti-multiple myeloma (MM) antigen peptides and the batches enriched with anti-leukemia antigen peptides are shown below.

[0173] Table 4: Batch-to-batch comparison of identity parameters and contributions of αβ and γδ T cell subsets*

[0174]

[0175]

[0176] *CD3 + CD8 + Figures for TCR subtype analysis are from different samples. + CD8 + The discrepancy with αβ T cells is due to different samples and different FCM gating strategies.

[0177] In the following experiments, phenotype is a measure of the total % of memory T cells relative to CD3+ cells. Characterized memory T cell populations include T stem cell memory (Tscm) and T central memory (Tcm) populations, both of which retain the ability of proliferation and self-renewal and T effector memory (Tem) cells. Characterized remaining populations include Temra and T initial cells.

[0178] Table 5 Comparison of phenotypes between batches: Tinitial, Tscm, Tcm, Tem, Temra

[0179]

[0180]

[0181] As demonstrated by the above experiments, the CD8+ T cell compositions disclosed herein directly engage with T cell receptors on initial and memory T cells to trigger the desired immune response. The CD8+ T cell compositions produced by the enrichment and amplification process are composed of T cells restricted by multi-antigen-specific CD8+ from endogenous libraries. Antigen-specific CD8+ T cell compositions include T memory stem cells. T memory stem cells and central memory T cells are helpful and critical for initial and long-term clinical responses. As assessed by effector cytokine production and target cell killing, antigen-specific CD8+ T cell compositions have a multifunctional phenotype. The E+E process also produces a natural immune response driven by different TCR libraries. In addition to robust αβT cell populations, there are also significant γδT cell populations in the amplified population, and the γδT cell populations include both Vδ1 cells and Vδ2 cells. γδT cells are believed to provide additional mechanisms for pathogen or cancer cell killing that are not HLA-dependent.

Claims

1. An isolated cell composition suitable for adoptive immunotherapy, comprising at least 10 6 The composition comprises CD8+T cells specific for one or more target peptide antigens, wherein the CD8+T cells in the composition are at least 50% central memory T cells and effector memory T cells, and comprise T memory stem cells (T SCM ),in, One or more target peptide antigens are selected from the group consisting of survivin, WT-1, PRAME, peptide epitopes of cyclin A1, and / or The one or more target peptide antigens are selected from peptide epitopes of PR3, XBP1-US, XBP1-SP, CD138, CS1, NY-ESO1, SOX2, EBV, influenza, CMV, RHAMM, Mart-1 / MelanA, gp100, CMVpp65, and influenza matrix protein M1.

2. The isolated cell composition of claim 1, wherein the CD8+ T cells are specific for at least 3 target peptide antigens, or at least 4 target peptide antigens, or at least 5 target peptide antigens.

3. The isolated cell composition of claim 1, wherein the specificity of T cells in the composition for a target peptide antigen is defined by MHC multimer staining.

4. The isolated cell composition of claim 1, wherein the target peptide antigen is a tumor-associated antigen.

5. The isolated cell composition of claim 4, wherein the target peptide antigen is an antigen associated with acute myeloid leukemia (AML) and is optionally selected from Table 1.

6. The isolated cell composition of claim 5, wherein the target peptide antigen comprises peptide epitopes of WT-1, PRAME, survivin and cyclin A1.

7. The isolated cell composition of claim 4, wherein the target peptide antigen is an antigen associated with multiple myeloma and optionally includes one or more of NY-ESO-1, WT-1, XBP1-US, XBP1-SP, CD138, CS1 and SOX2 antigens.

8. The isolated cell composition of claim 7, wherein one or more of the target peptide antigens are selected from Table 2.

9. The isolated cell composition of claim 1, wherein one or more target peptide antigens are viral antigens, and wherein one or more of the target peptide antigens are selected from Table 2.

10. The isolated cell composition of any one of claims 1 and 9, wherein the cell composition is at least 90% T cells.

11. The isolated cell composition of claim 10, wherein at least 5% of the CD8+ T cells are specific for a target peptide antigen.

12. The isolated cell composition of claim 11, wherein at least 10% of the CD8+ T cells are specific for a target peptide antigen.

13. The isolated cell composition of claim 11, wherein at least 15% of the CD8+ T cells are specific for a target peptide antigen.

14. The isolated cell composition of claim 11, wherein at least 30% of the CD8+ T cells are specific for a target peptide antigen.

15. The isolated cell composition of any one of claims 1 or 14, wherein the cell composition further comprises CD8+T cells specific for bacterial, viral and / or fungal pathogens, optionally wherein the CD8+T cells specific for bacterial, viral or fungal pathogens include T cells specific for antigens of influenza, CMV, EBV and / or adenovirus.

16. The isolated cell composition of any one of claims 1 to 15, wherein the CD8+ T cells are at least about 1% of T memory stem cells.

17. The isolated cell composition of any one of claims 1 to 16, wherein greater than 95% of the CD8+ T cells comprise a memory phenotype.

18. The isolated cell composition of claim 17, wherein the CD8+ T cells are at least 70% of central memory T cells and effector memory T cells.

19. The isolated cell composition of claim 17, wherein the CD8+ T cells are at least 80% of central memory T cells and effector memory T cells.

20. The isolated cell composition of claim 17, wherein the CD8+ T cells are at least 90% central memory T cells and effector memory T cells.

21. The isolated cell composition of any one of claims 17 to 20, wherein the CD8+T cells specific for one or more target peptide antigens are at least 50% of central memory T cells and effector memory T cells, or at least 80% of central memory T cells and effector memory T cells.

22. The isolated cell composition of any one of claims 17 to 21, wherein the CD8+ T cells are less than 10% terminally differentiated.

23. The isolated cell composition of any one of claims 17 to 22, wherein the composition comprises less than 5% naive T cells (TN).

24. The isolated cell composition of any one of claims 1 to 23, wherein at least 40% of the CD8+ T cells exhibit a polyfunctional phenotype upon activation.

25. The isolated cell composition of any one of claims 1 to 24, wherein the composition further comprises γδ T cells.